Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 2/20 | 0.33 |
| ▸ | EDNRB | P24530 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16021517 | 0.86 | TP53 (0.35) | MAPK1 | |
| SCHEMBL22996180 | 0.82 | LMNA (0.31) | LMNA | |
| SCHEMBL2612162 | 0.80 | — | — | |
| SCHEMBL27042873 | 0.77 | NOS2 (0.37) | POLB | |
| SCHEMBL12385469 | 0.73 | — | — | |
| SCHEMBL11608982 | 0.73 | — | — | |
| SCHEMBL17755899 | 0.73 | FFAR4 (0.38) | LMNAL3MBTL1 | |
| SCHEMBL8237746 | 0.71 | LMNA (0.44) | LMNAL3MBTL1 | |
| SCHEMBL14923170 | 0.70 | CYP1A2 (0.32) | MAPK1 | |
| SCHEMBL12926069 | 0.70 | LMNA (0.37) | LMNAMAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220267300-A1 | SULFONAMIDE DERIVATIVES AND USES THEREOF | NodThera Limited (GB) | 2022-08-25 | — | — | US | disclosed |
| US-20110130386-A1 | DNA-PK INHIBITORS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130386-A1 | DNA-PK INHIBITORS | DNA2, TOP1, XRCC6 | EDNRA 1675/4885EDNRB 1379/4885LMNA 361/4885 |
| US-20220267300-A1 | SULFONAMIDE DERIVATIVES AND USES THEREOF | IL1B, IL1A, CASP1 | EDNRA 3333/4885EDNRB 3761/4885LMNA 2527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.